Boston Scientific, a global medical device company, with its continued commitment towards advance therapy adoption in interventional cardiology for treating Complex and High-Risk Coronary Intervention (CHIP) patients, has collaborated with a leading interventional Cardiologist Dr. Masahisa Yamane, Director of Cardiovascular Division, Sekishinkai Saitama Hospital, Saitama to proctor a set of coronary intervention workshops in India.

Keeping in line with the mission to transform patient lives, Boston Scientific is regularly striving to adopt newer and advanced treatment mechanisms that improve the health of patients around the world. In one such endeavor, Max Super Speciality Hospital, Shalimar Bagh hosted a workshop today in collaboration with Boston Scientific and Dr. Masahisa Yamane from Japan, focusing on providing a knowledge sharing platform for Interventional Cardiologists to discuss and develop expertise in adoption of latest technologies for complex and high - risk angioplasties. The workshop will also spread across India including Delhi, Lucknow, Hyderabad, Ahmedabad, and Patna between February 3, 2020 and February 7, 2020.

Eminent cardiologists of the Max Super Speciality Hospital, Shalimar Bagh hospital participated in the workshop that witnessed complex high-risk angioplasties, using advanced technologies like Intravascular Ultrasound (IVUS) and Rotational Atherectomy, that are now providing the physician with critical information about the diseased area and aiding in selection of optimal treatment methods for treating artery blockages and coronary complexities.

Usage of such advanced technologies may provide better outcomes in the long term for patients, thereby improving the quality of life.

Dr. Naveen Bhamri, Director and Head of Department, Cardiology- Max Hospital, Shalimar Bagh said,’’ We are extremely happy to collaborate with Boston Scientific and the international faculty for this workshop. The cardiology scenario is witnessing a paradigm shift in treatment mechanisms and technologies. Cases related to chronic total occlusion of coronary arteries, and calcification of the blood vessels is on the rise and so ongoing innovation in medical technology may enables physicians to provide better treatment and improve quality of life for patients with cardiovascular diseases.”

Technology is paving the way for improved medical treatment to help people suffering from cardiovascular diseases (CVD). According to WHO, an estimated 17.9 million people died from CVD in 2016, representing 31 percent of all global deaths. Out of the 17 million premature deaths, under the age of 70, 37 percent were caused by CVDs *.